A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Pertuzumab (PERJETA)

HER2/neu Receptor Antagonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2012-06-08
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$16.6M in CY2024 Part D spend2K claims · 438 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Pertuzumab used for?

Pertuzumab is a HER2/neu Receptor Antagonist medication tracked in Medicare Part D.

Is there a generic for Pertuzumab?

No. Pertuzumab is brand-only with no generic equivalents currently in market.

How much does my plan pay for Pertuzumab?

NADAC pricing data not currently available for this drug.

Is Pertuzumab on the FDA shortage list?

No. Pertuzumab is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

HER2/neu Receptor Antagonist6 alternatives in D1
01
Margetuximab-Cmkb
Brand: MARGENZA
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Ontruzant
HER2/neu Receptor Antagonist
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Trastuzumab
Brand: HERZUMA
Lowest NADAC
0Generic mfrs
$7.2MCY24 Part D spend
Compare →
04
Trastuzumab-Anns
Brand: Kanjinti
Lowest NADAC
0Generic mfrs
$2.3MCY24 Part D spend
Compare →
05
Trastuzumab-Dkst
Brand: OGIVRI
Lowest NADAC
0Generic mfrs
$1.8MCY24 Part D spend
Compare →
06
Trastuzumab-Qyyp
Brand: Trazimera
Lowest NADAC
0Generic mfrs
$18.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.